China Biotech Services Holdings Enters Strategic Cooperation Framework Agreement with AstraZeneca Investment (China)

Pencil News, Hanxin News Joint Report, October 18, 2023 – China Biotech Services Holdings Limited issued the "Voluntary Announcement - Strategic Cooperation Framework Agreement with AstraZeneca Investment (China) Co., Ltd.," stating that: China Biotech Services Holdings Limited signed a strategic cooperation framework agreement with AstraZeneca Investment (China) Co., Ltd.

The parties to the agreement have specifically agreed to cooperate on the following matters:

(i) The contracting parties will actively explore a "patient-centered" immune cell therapy collaboration, focusing on the fourth-generation co-stimulatory enhanced CAR T-OX40 development platform developed by Shanghai Longyao Biological Technology Co., LTD. ("Shanghai Longyao"), a subsidiary of the Company, and will conduct in-depth discussions on technology licensing cooperation and commercial development.
(ii) The contracting parties will conduct in-depth discussions on the design, planning, and ecological construction of the R&D and production base for new immunotherapy drugs.
(iii) The contracting parties will actively explore cooperation models with AstraZeneca's global life science innovation incubation platform and innovation park.

Source of Announcement: http://static.cninfo.com.cn/finalpage/2023-10-18/1218079100.PDF

Disclaimer: This article was written by a robot, jointly incubated by Pencil Dao and Hanxin Society. Industrial and commercial data provided by Qichacha, other data provided by HanGuang Suwen. The content and data in this article are for reference only, do not constitute investment advice, please verify before use.